OS Therapies Incorporated is a clinical-stage biopharmaceutical company developing immunotherapy and drug conjugate treatments for osteosarcoma, a bone cancer affecting children and young adults, as well as other solid tumors. The company's lead product, OST-HER2, is a genetically engineered Listeria-based immunotherapy designed to stimulate immune responses against HER2-expressing cancer cells and is advancing toward regulatory submission for osteosarcoma, with plans to expand to breast, lung, and esophageal cancers. The company also develops the OST-tADC platform, a next-generation antibody-drug conjugate technology with tunable payload release properties. OS Therapies currently generates no product revenue but intends to commercialize approved therapies through direct sales to oncologists and cancer centers in the United States, as well as through potential licensing partnerships with larger pharmaceutical companies.